170 related articles for article (PubMed ID: 35174853)
1. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
[TBL] [Abstract][Full Text] [Related]
2. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
3. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of a muscle ankyrin-repeat protein, Arpp, in paraffin-embedded tumors: evaluation of Arpp as a tumor marker for rhabdomyosarcoma.
Ishiguro N; Motoi T; Osaki M; Araki N; Minamizaki T; Moriyama M; Ito H; Yoshida H
Hum Pathol; 2005 Jun; 36(6):620-5. PubMed ID: 16021567
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V; Walter B; Fend F; Overkamp M; Rothermundt C; Lopez CD; Schittenhelm MM; Kampa-Schittenhelm KM
BMC Cancer; 2022 Jul; 22(1):725. PubMed ID: 35780096
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group study.
Nicol K; Savell V; Moore J; Teot L; Spunt SL; Qualman S;
Pediatr Dev Pathol; 2007; 10(2):89-97. PubMed ID: 17378682
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
Tuohy JL; Byer BJ; Royer S; Keller C; Nagai-Singer MA; Regan DP; Seguin B
Vet Pathol; 2021 May; 58(3):516-526. PubMed ID: 33691532
[TBL] [Abstract][Full Text] [Related]
8. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
[TBL] [Abstract][Full Text] [Related]
10. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
11. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
[TBL] [Abstract][Full Text] [Related]
12. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma.
Hosoyama T; Aslam MI; Abraham J; Prajapati SI; Nishijo K; Michalek JE; Zarzabal LA; Nelon LD; Guttridge DC; Rubin BP; Keller C
Clin Cancer Res; 2011 May; 17(9):2757-66. PubMed ID: 21536546
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
Saito H; Suzuki N
Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
[TBL] [Abstract][Full Text] [Related]
15. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.
Xu J; Timares L; Heilpern C; Weng Z; Li C; Xu H; Pressey JG; Elmets CA; Kopelovich L; Athar M
Cancer Res; 2010 Aug; 70(16):6566-76. PubMed ID: 20682800
[TBL] [Abstract][Full Text] [Related]
16. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.
Blum JM; Añó L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG
Cell Rep; 2013 Nov; 5(4):933-40. PubMed ID: 24239359
[TBL] [Abstract][Full Text] [Related]
17. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
18. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
19. Experimental induction of rhabdomyosarcoma in mice with fractionated doses of beta-irradiation.
Gupta A; Andrews KL; McDaniel KM; Nagle RB; Bowden GT
J Cancer Res Clin Oncol; 1999; 125(5):257-67. PubMed ID: 10359130
[TBL] [Abstract][Full Text] [Related]
20. You can win by losing: p53 mutations in rhabdomyosarcomas.
Post SM; Lozano G
J Pathol; 2010 Oct; 222(2):124-8. PubMed ID: 20821751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
